A Phase 3 Double-Blind Placebo-Controlled Evaluation of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Naive and Experienced Genotype 1, 2, 4, 5, 6 HCV Infected Patients with and without cirrhosis: Results of the ASTRAL-1 Study
Journal article published in 2015 by
Jordan J. Feld,
Jordan J. Feld,
Kosh Agarwal 
,
Kosh Agarwal,
Christophe Hezode,
Christophe Hezode,
Tarik Asselah,
Tarik Asselah,
Peter J. Ruane,
Peter J. Ruane,
Norbert Gruener,
Norbert Gruener,
Armand Abergel,
Armand Abergel,
Alessandra Mangia
and other authors.
,
Kosh Agarwal,
Christophe Hezode,
Christophe Hezode,
Tarik Asselah,
Tarik Asselah,
Peter J. Ruane,
Peter J. Ruane,
Norbert Gruener,
Norbert Gruener,
Armand Abergel,
Armand Abergel,
Alessandra Mangia
and other authors.
